|
TELAVANCIN
 INN TELAVANCIN
|
cas 372151-71-8 |
CLASS ANTIINFECTIVE LIPOGLYCOPEPTIDE ANTIBACTERIALS SKIN INFECTION GRAM-POSITIVE BACTERIA SYNTHETIC DERIVATIVE OF VANCOMYCIN INHIBITS BACTERIAL CELL WALL SYNTHESIS BY INTERFERING WITH THE POLYMERIZATION AND CROSS-LINKING OF PEPTIDOGLYCAN |
ROUTE ( list) INTRAVENOUS INJECTION |
ATC code
J01XA03 |
PK parameters VD 9.4 LITER (65 KILOGRAM) Cl 0.9 LITER / HOUR (65 KILOGRAM) PPB 90 PERCENT t1/2 8 HOUR
SolubilitySLIGHTLY SOLUBLE IN WATER
|
Target - |
DrugCentral Unknown |
Download SDF file |
Vancomycin, N3''-[2-(decylamino)ethyl]-29-[[(phosphonomethyl)amino]methyl]- (REACH) Formula: C80H106Cl2N11O27P Calculated chemical properties: MW 1752.60 NB_atoms 121 XLogP 0.09 PSA 547.601 NB_HD 21 NB_HA 38 fsp3 0.53 Lipinski(0=no;1=yes) 0 |
FDA NDA 022110 ( label) INN (TELAVANCIN HYDROCHLORIDE) VIBATIV (CUMBERLAND) APPROVAL= AP YEAR= 2009 NEWMOLECULARENTITY NDA 022407 ( label) INN (TELAVANCIN) VIBATIV (THERAVANCE INC) APPROVAL= AP YEAR= 2013 NEWAPPLICATION |
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |